Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Repare Therapeutics Company

RPTX
US7602731025
A2P7AV

Price

3.43
Today +/-
+0.07
Today %
+2.36 %
P

Repare Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Repare Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Repare Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Repare Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Repare Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Repare Therapeutics Stock Price History

DateRepare Therapeutics Price
10/18/20243.43 undefined
10/17/20243.35 undefined
10/16/20243.42 undefined
10/15/20243.36 undefined
10/14/20243.39 undefined
10/11/20243.14 undefined
10/10/20243.27 undefined
10/9/20243.31 undefined
10/8/20243.45 undefined
10/7/20243.45 undefined
10/4/20243.75 undefined
10/3/20243.46 undefined
10/2/20243.45 undefined
10/1/20243.47 undefined
9/30/20243.44 undefined
9/27/20243.44 undefined
9/26/20243.50 undefined
9/25/20243.38 undefined
9/24/20243.37 undefined
9/23/20243.38 undefined

Repare Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Repare Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Repare Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Repare Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Repare Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Repare Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Repare Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Repare Therapeutics’s growth potential.

Repare Therapeutics Revenue, EBIT and net profit per share

DateRepare Therapeutics RevenueRepare Therapeutics EBITRepare Therapeutics Net Income
2028e159.22 M undefined-116.12 M undefined-12.12 M undefined
2027e52.7 M undefined-168.8 M undefined-102.4 M undefined
2026e40.96 M undefined-156.75 M undefined-120.28 M undefined
2025e9.86 M undefined-163.99 M undefined-139.98 M undefined
2024e59.75 M undefined-108.95 M undefined-97.72 M undefined
202351.13 M undefined-116.22 M undefined-93.8 M undefined
2022131.8 M undefined-19.8 M undefined-29 M undefined
20217.6 M undefined-108.7 M undefined-106.9 M undefined
2020100,000 undefined-53.5 M undefined-53.4 M undefined
20190 undefined-26.4 M undefined-27.2 M undefined
20180 undefined-12.8 M undefined-14.3 M undefined
20170 undefined-6.2 M undefined-7.8 M undefined

Repare Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20172018201920202021202220232024e2025e2026e2027e2028e
00007131515994052159
-----1,771.43-61.0715.69-84.75344.4430.00205.77
------------
000000000000
-6-12-26-53-108-19-116-108-163-156-168-116
-----1,542.86-14.50-227.45-183.05-1,811.11-390.00-323.08-72.96
-7-14-27-53-106-29-93-97-139-120-102-12
-100.0092.8696.30100.00-72.64220.694.3043.30-13.67-15.00-88.24
35353536.937.841.942.0900000
------------
Details

Keystats

ⓘ

Revenue and Growth

The Repare Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Repare Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
201820192020202120222023
           
10.794.8333.7341.9343.9223.63
000000
000000
000000
0.30.76.76.35.74.75
1195.5340.4348.2349.6228.38
1.73.48.613.19.67.54
000000
000002.28
000000
000000
0.20.71.94.20.50.4
1.94.110.517.310.110.21
12.999.6350.9365.5359.7238.59
           
31.9136384.3480.7482483.35
0.33.85.91837.261.81
-22.7-49.9-103.4-210.3-239.3-333.11
0000-40028
000000
9.589.9286.8288.4279.5212.08
1.22.12.32.30.52.4
0.41.76.52023.526.26
0.20.52.312.854.610.42
000000
000000
1.84.311.135.178.639.08
000000
000000
2.58.659.245.25.92.74
2.58.659.245.25.92.74
4.312.970.380.384.541.82
13.8102.8357.1368.7364253.9
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Repare Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Repare Therapeutics's financial health and stability.

Assets

Repare Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Repare Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Repare Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Repare Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (k)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (k)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
2017201820192020202120222023
-7-14-27-53-106-29-93
00001,0001,0001,000
000-1-230
0064374-55
1226273944
000001,0000
00000104
-6-12-18-6-850-127
-10-1-2-10-1
-10-1-9-1-17578
000-70-17579
0000000
1,000000000
2801032479500
3001032479500
-------
0000000
23-13842318-174-48
-7.17-13.2-19.73-8.32-87.49-0.28-129.1
0000000

Repare Therapeutics stock margins

The Repare Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Repare Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Repare Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Repare Therapeutics's sales revenue. A higher gross margin percentage indicates that the Repare Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Repare Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Repare Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Repare Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Repare Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Repare Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Repare Therapeutics Margin History

Repare Therapeutics Gross marginRepare Therapeutics Profit marginRepare Therapeutics EBIT marginRepare Therapeutics Profit margin
2028e0 %-72.93 %-7.61 %
2027e0 %-320.31 %-194.31 %
2026e0 %-382.69 %-293.67 %
2025e0 %-1,664.07 %-1,420.39 %
2024e0 %-182.34 %-163.55 %
20230 %-227.3 %-183.44 %
20220 %-15.02 %-22 %
20210 %-1,430.26 %-1,406.58 %
20200 %-53,500 %-53,400 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

Repare Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Repare Therapeutics earnings per share therefore indicates how much revenue Repare Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Repare Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Repare Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Repare Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Repare Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Repare Therapeutics Revenue, EBIT and net profit per share

DateRepare Therapeutics Sales per ShareRepare Therapeutics EBIT per shareRepare Therapeutics Earnings per Share
2028e3.75 undefined0 undefined-0.29 undefined
2027e1.24 undefined0 undefined-2.41 undefined
2026e0.96 undefined0 undefined-2.83 undefined
2025e0.23 undefined0 undefined-3.3 undefined
2024e1.41 undefined0 undefined-2.3 undefined
20231.21 undefined-2.76 undefined-2.23 undefined
20223.15 undefined-0.47 undefined-0.69 undefined
20210.2 undefined-2.88 undefined-2.83 undefined
20200 undefined-1.45 undefined-1.45 undefined
20190 undefined-0.75 undefined-0.78 undefined
20180 undefined-0.37 undefined-0.41 undefined
20170 undefined-0.18 undefined-0.22 undefined

Repare Therapeutics business model

Repare Therapeutics Inc is a biotechnology company specializing in the development of precision medicines for the treatment of cancer. It was founded in 2016 by four leading scientists and is headquartered in Montreal, Canada. The company utilizes an innovative and unique approach called CRISPR-Cas9 to identify and target genetic mutations in cancer cells. The history of Repare Therapeutics Inc stems from a collaboration among renowned cancer researchers. In 2016, the founders, who already had extensive experience in drug development, pooled their resources to create a new generation of cancer therapies. Using the innovative CRISPR-Cas9 system, they were able to specifically identify genetic alterations in cancer cells and significantly reduce tumor burden. Since its inception, the company has formed strong partnerships and successfully raised capital to continue its research and development. Repare Therapeutics has a unique business model focused on developing precision medicine for patients with specific types of cancer. The company combines CRISPR-Cas technology and machine learning to identify genetic mutations in cancer cells and correlate them with an extensive dataset of available clinical studies. This systematic approach allows for faster and more precise identification of suitable target molecules that may serve as potential therapy options for cancer. Repare Therapeutics specializes in quickly and efficiently developing molecules that target these target molecules and advancing them through clinical trials. The company distributes its precision medicines in three different sectors: oncology, therapeutics, and research. The oncology sector specializes in the development of precision medicines for the treatment of cancer. The therapeutics sector offers solutions for the medical care of patients through the development of novel therapies. The research department focuses on developing new precision medicines and advancing innovations in cancer research. Repare Therapeutics offers various products tailored to the needs of cancer patients. The CRISPR-Cas9 technology is being used to advance multiple clinical programs aimed at regulating gene expression in tumor cells and enhancing the effectiveness of cancer therapies. The company's flagship product, RP-3500, is a precision medicine specifically targeted against a gene called KRAS, which plays a crucial role in many types of cancer. The medication has demonstrated strong efficacy in clinical trials and is currently in Phase 1 studies. In summary, Repare Therapeutics Inc is an innovative biotechnology company specializing in the development of precision medicines against cancer. The use of CRISPR-Cas9 technology in combination with machine learning allows for faster identification of suitable target molecules that may serve as potential therapy options for cancer. The company offers various precision medicines that benefit cancer patients. With its numerous research programs and clinical trials, Repare Therapeutics is poised to become a leading player in cancer treatment and research. Repare Therapeutics is one of the most popular companies on Eulerpool.com.

Repare Therapeutics SWOT Analysis

Strengths

Repare Therapeutics Inc possesses several strengths that contribute to its competitive advantage in the market:

  • Strong Intellectual Property Portfolio: Repare Therapeutics has a robust portfolio of intellectual property rights, including patents and trade secrets, which protect its innovative products and technologies.
  • Experienced Management Team: The company is led by a highly skilled management team with extensive experience in the biotechnology industry. Their expertise provides strategic direction and effective decision-making.
  • Cutting-Edge Research and Development: Repare Therapeutics invests significantly in research and development to discover and develop novel therapies. This commitment to innovation enables the company to stay ahead of competitors.
  • Partnerships and Collaborations: The company has established strategic partnerships with leading pharmaceutical companies, allowing for collaborative research projects and potential access to additional resources and markets.
  • Strong Financial Position: Repare Therapeutics enjoys a solid financial backing, allowing it to fund its operations, research initiatives, and clinical trials without significant financial constraints.

Weaknesses

While Repare Therapeutics has many strengths, it also faces certain weaknesses that may hinder its growth and success:

  • Dependence on Limited Product Portfolio: The company's success heavily relies on the performance and market acceptance of its limited product portfolio. Failure of these products could adversely impact its future prospects.
  • Early Stage of Drug Development: Most of Repare Therapeutics' products are in the early stages of development, making them subject to various risks, such as regulatory hurdles, clinical trial failures, and unpredictable market dynamics.
  • Reliance on External Funding: As a research-intensive company, Repare Therapeutics heavily relies on external funding sources, such as venture capital investments and collaborations. Economic downturns or limited availability of funding could pose a challenge.

Opportunities

Repare Therapeutics can capitalize on several opportunities to fuel its growth and gain a competitive edge:

  • Market Expansion: The growing demand for innovative therapies presents an opportunity for Repare Therapeutics to expand its market reach and target a wider patient population.
  • Advancements in Technology: Technological advancements, such as gene editing and precision medicine, provide opportunities for Repare Therapeutics to develop breakthrough therapies with improved efficacy and safety profiles.
  • Emerging Markets: Repare Therapeutics can explore partnerships and market entry strategies to tap into emerging markets, where there may be high unmet medical needs and faster approval processes.

Threats

Despite its strengths and opportunities, Repare Therapeutics must also navigate potential threats that could impact its growth and profitability:

  • Regulatory Challenges: The biopharmaceutical industry is heavily regulated, and Repare Therapeutics may face challenges in obtaining regulatory approvals for its products. Delays in approvals or changes in regulations could hinder the company's progress.
  • Intense Competition: The biotechnology sector is highly competitive, with numerous established players and emerging startups. Repare Therapeutics must stay ahead of competitors in terms of research, product development, and commercialization efforts.
  • Market Volatility: Fluctuations in the global financial markets, changes in healthcare policies, and shifts in consumer preferences can all impact the market demand for Repare Therapeutics' products and its ability to generate revenue.
  • Intellectual Property Risks: Intellectual property infringement by competitors or challenges to the company's patents and trade secrets could disrupt Repare Therapeutics' business and limit its ability to protect its innovations.

Repare Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Repare Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Repare Therapeutics shares outstanding

The number of shares was Repare Therapeutics in 2023 — This indicates how many shares 42.093 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Repare Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Repare Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Repare Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Repare Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Repare Therapeutics.

Repare Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.89 -0.82  (7.44 %)2024 Q2
3/31/20240.02 0.3  (1,775 %)2024 Q1
12/31/2023-0.37 -0.67  (-83.21 %)2023 Q4
9/30/2023-0.88 -0.45  (48.62 %)2023 Q3
6/30/2023-0.8 -0.28  (64.81 %)2023 Q2
3/31/2023-0.82 -0.83  (-0.64 %)2023 Q1
12/31/2022-0.74 -0.75  (-1.89 %)2022 Q4
9/30/2022-0.91 1.71  (288.78 %)2022 Q3
6/30/2022-0.86 -0.91  (-5.37 %)2022 Q2
3/31/2022-0.87 -0.83  (4.9 %)2022 Q1
1

Repare Therapeutics shareholders

%
Name
Stocks
Change
Date
19.53354 % BVF Partners L.P.8,291,988012/31/2022
7.82683 % OrbiMed Advisors, LLC3,322,488012/31/2022
6.99094 % Versant Ventures2,967,652-577,21012/29/2022
6.59629 % Cowen Investment Management LLC2,800,126-269,72112/31/2022
6.42546 % Deep Track Capital LP2,727,606-400,06112/31/2022
6.32367 % Redmile Group, LLC2,684,396012/31/2022
5.71980 % ARK Investment Management LLC2,428,055-203,97312/31/2022
5.28301 % MPM Capital Inc.2,242,636012/31/2022
4.51832 % T. Rowe Price Investment Management, Inc.1,918,026155,28312/31/2022
3.86301 % BioImpact Capital LLC1,639,849012/31/2022
1
2
3
4
5
...
10

Repare Therapeutics Executives and Management Board

Mr. Lloyd Segal58
Repare Therapeutics President, Chief Executive Officer, Director (since 2016)
Compensation 3.91 M
Dr. Maria Koehler66
Repare Therapeutics Executive Vice President, Chief Medical Officer
Compensation 3.67 M
Dr. Michael Zinda51
Repare Therapeutics Executive Vice President, Chief Scientific Officer (since 2019)
Compensation 3.65 M
Mr. Steve Forte43
Repare Therapeutics Chief Financial Officer, Executive Vice President
Compensation 2.31 M
Mr. Thomas Civik53
Repare Therapeutics Independent Chairman of the Board
Compensation 946,580
1
2
3

Repare Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Cyteir Therapeutics Stock
Cyteir Therapeutics
SupplierCustomer0,130,120,790,95--
Bristol-Myers Squibb Stock
Bristol-Myers Squibb
SupplierCustomer-0,040,23-0,74-0,83-0,29-
Ono Pharmaceutical Stock
Ono Pharmaceutical
SupplierCustomer-0,72-0,22-0,69-0,79-0,79-
1

Most common questions regarding Repare Therapeutics

What values and corporate philosophy does Repare Therapeutics represent?

Repare Therapeutics Inc represents values of innovation, collaboration, and patient-centricity. As a leading biotech company, Repare is committed to revolutionizing cancer treatments through its pioneering synthetic lethality approach. By harnessing the power of precision medicine, Repare aims to develop targeted therapies that address the underlying mechanisms of DNA damage repair in cancer cells. The company's corporate philosophy emphasizes scientific excellence, integrity, and a strong sense of responsibility towards advancing human health. Repare Therapeutics Inc prioritizes the needs of patients and strives to make a significant impact in the fight against cancer through cutting-edge research and development.

In which countries and regions is Repare Therapeutics primarily present?

Repare Therapeutics Inc primarily operates in the United States and Canada.

What significant milestones has the company Repare Therapeutics achieved?

Repare Therapeutics Inc, a leading biotechnology company, has accomplished several significant milestones. Firstly, it successfully completed its initial public offering (IPO) in June 2020, raising substantial capital to fuel its growth. Additionally, the company has made remarkable strides in advancing its innovative precision oncology platform, known as SNIPRx®, which utilizes synthetic lethality to target specific cancer vulnerabilities. Repare Therapeutics Inc has also forged strategic collaborations with renowned pharmaceutical companies, such as Bristol Myers Squibb, to further enhance its research and development efforts. These achievements demonstrate Repare Therapeutics Inc's commitment to revolutionizing cancer treatments through groundbreaking therapeutics and strategic partnerships.

What is the history and background of the company Repare Therapeutics?

Repare Therapeutics Inc is a pharmaceutical company specializing in precision oncology. Founded in 2016, the company is headquartered in Cambridge, Massachusetts, and has a research and development hub in Montreal, Canada. Repare Therapeutics aims to develop innovative drugs that target specific vulnerabilities in cancer cells through its proprietary synthetic lethality approach. With a focus on DNA repair pathways, the company harnesses the power of genomics, bioinformatics, and machine learning to identify potential drug targets. Repare Therapeutics has made significant advancements in novel therapeutics and is committed to revolutionizing cancer treatment through its cutting-edge research and development efforts.

Who are the main competitors of Repare Therapeutics in the market?

The main competitors of Repare Therapeutics Inc in the market include leading biopharmaceutical companies like AstraZeneca, GlaxoSmithKline, Pfizer, and Novartis. These companies also focus on developing innovative and effective cancer treatments, similar to Repare Therapeutics Inc. As Repare Therapeutics Inc strives to advance its precision oncology pipeline and leverage its proprietary synthetic lethality approach, it faces competition from these established players in the industry.

In which industries is Repare Therapeutics primarily active?

Repare Therapeutics Inc is primarily active in the biotechnology industry.

What is the business model of Repare Therapeutics?

Repare Therapeutics Inc. is a pharmaceutical company that focuses on developing precision oncology drugs. Their business model revolves around utilizing synthetic lethality, a cutting-edge approach to target specific genetic vulnerabilities in cancer cells. By exploiting the DNA repair pathways unique to cancer cells, Repare aims to develop novel therapies with enhanced efficacy and limited side effects. Their research and development efforts are driven by a robust pipeline of small molecule candidates, aiming to address the unmet medical needs of cancer patients. Repare Therapeutics Inc. is committed to revolutionizing cancer treatment through innovative precision medicine solutions.

What is the P/E ratio of Repare Therapeutics 2024?

The Repare Therapeutics P/E ratio is -1.48.

What is the P/S ratio of Repare Therapeutics 2024?

The Repare Therapeutics P/S ratio is 2.42.

What is the Quality Investing of Repare Therapeutics?

The Quality Investing for Repare Therapeutics is 4/10.

What is the revenue of Repare Therapeutics 2024?

The expected Repare Therapeutics revenue is 59.75 M USD.

How high is the profit of Repare Therapeutics 2024?

The expected Repare Therapeutics profit is -97.72 M USD.

What is the business model of Repare Therapeutics

The company Repare Therapeutics Inc is a rising biotechnology company specializing in the discovery and development of new drugs for the treatment of cancer. The company was founded in 2016 and is headquartered in Montreal, Canada. Repare Therapeutics' business model is based on researching the fundamental mechanisms that lead to the development of cancer. The company uses an innovative approach called Synthetic Lethality to specifically identify weaknesses in cancer cells and then develop targeted drugs against these weaknesses. The company operates in two main areas, the discovery of new drugs and the clinical development of already identified candidates. Repare Therapeutics conducts intensive research and development to discover and develop new drug candidates. These drugs are then tested in clinical studies to evaluate their effectiveness and safety. Repare Therapeutics specializes in the development of drugs against cancer types that are traditionally difficult to treat. One such cancer is prostate cancer, which often exhibits high resistance to standard chemotherapy drugs. Repare Therapeutics focuses on innovative approaches, such as the development of drugs that target specific weaknesses in the DNA of cancer cells. In addition to drug development, Repare Therapeutics also collaborates with other biotechnology and pharmaceutical companies. The goal of these partnerships is to expand Repare Therapeutics' portfolio and further advance the research and development of new drugs. Repare Therapeutics' business model is focused on research and development, aiming to develop highly effective drugs against difficult-to-treat types of cancer. The company focuses on innovative approaches to specifically identify weaknesses in cancer cells. Through partnerships with other companies, the portfolio is expanded and research and development are advanced. Overall, Repare Therapeutics is a promising company that focuses on one of the biggest challenges in medicine: the development of effective and safe drugs for the treatment of cancer. With its innovative approaches and strong partnerships, the company has the potential to play a significant role in cancer research and contribute to better treating this disease in the future.

What is the Repare Therapeutics dividend?

Repare Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Repare Therapeutics pay dividends?

The dividend cannot currently be calculated for Repare Therapeutics or the company does not pay out a dividend.

What is the Repare Therapeutics ISIN?

The ISIN of Repare Therapeutics is US7602731025.

What is the Repare Therapeutics WKN?

The WKN of Repare Therapeutics is A2P7AV.

What is the Repare Therapeutics ticker?

The ticker of Repare Therapeutics is RPTX.

How much dividend does Repare Therapeutics pay?

Over the past 12 months, Repare Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Repare Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Repare Therapeutics?

The current dividend yield of Repare Therapeutics is .

When does Repare Therapeutics pay dividends?

Repare Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Repare Therapeutics?

Repare Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Repare Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Repare Therapeutics located?

Repare Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Repare Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Repare Therapeutics from 10/22/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/22/2024.

When did Repare Therapeutics pay the last dividend?

The last dividend was paid out on 10/22/2024.

What was the dividend of Repare Therapeutics in the year 2023?

In the year 2023, Repare Therapeutics distributed 0 USD as dividends.

In which currency does Repare Therapeutics pay out the dividend?

The dividends of Repare Therapeutics are distributed in USD.

All fundamentals about Repare Therapeutics

Our stock analysis for Repare Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Repare Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.